Clinical trial
An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome
NCT01013480 is registered in ClinicalTrials.gov with Seaside Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome
- Lead sponsor
- Seaside Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 30, 2009
- Completion date
- December 31, 2012
- Enrollment
- 45 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.